ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

Alessandro Villa, DDS, PhD, MPH, & Sook Bin Woo, DMD, MMSc  |  October 13, 2015

Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

Filed under:Conditions Tagged with:ClinicalOsteonecrosispatient carerheumatologyrhuematologist

Transatlantic Divide: How U.S. Pays Three Times More for Drugs

Reuters  |  October 13, 2015

LONDON (Reuters)—U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters. The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such…

Filed under:Drug Updates Tagged with:costsdrugpharmaceutical company

Immunotherapy May Be Effective for Some Patients with Autoimmune Cerebellar Ataxia

Will Boggs, MD  |  October 7, 2015

NEW YORK (Reuters Health)—Immunotherapy appears to yield neurological improvements in some patients with autoimmune cerebellar ataxia, especially those with nonparaneoplastic disorders, researchers report. “I was surprised that so many patients responded to immunotherapy (steroids, intravenous immunoglobulin (IVIg), and plasma exchange) and remained ambulatory,” Dr. Andrew McKeon from Mayo Clinic in Rochester, Minn., told Reuters Health…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Autoimmune Cerebellar AtaxiaAutoimmune diseaseCorticosteroidsimmunoglobulinimmunotherapyNeurologyrituximab

Biotechs Extend Selloff as Pricing Concerns Intensify

Caroline Valetkevitch & Bill Berkrot  |  October 7, 2015

NEW YORK (Reuters)—U.S. biotech shares extended their recent downward spiral on Tuesday as concerns about drug pricing continued to plague the sector while disappointing news from Illumina and other companies added to selling pressure. The Nasdaq Biotechnology index, down 4%, has now fallen about 17% since just before Hillary Clinton, front-runner to be the Democratic nominee…

Filed under:Drug Updates

Doctors Often Uncomfortable Soliciting Donations for Patients

Kathryn Doyle  |  October 3, 2015

NEW YORK (Reuters Health)—Many doctors are asked to seek donations from grateful patients after successful cancer treatment, but most physicians are uncomfortable with this idea and feel a conflict of interest, according to a new study. “There are ethical ways of seeking donations from patients who have the means and want to give back,” Dr….

Filed under:Practice SupportProfessional Topics Tagged with:FundraisingPhilanthropyphysician

Novartis Biosimilar Takes Aim at Amgen’s Enbrel

Michael Shields & Ben Hirschler  |  October 2, 2015

ZURICH (Reuters)—The U.S. Food and Drug Administration has accepted Novartis unit Sandoz’s regulatory submission for approval of a biosimilar copy of Amgen’s blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said on Friday. Enbrel, or etanercept as the drug is known generically, is a big prize since it was the world’s fifth-biggest selling medicine in 2014…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Amgenanti-TNF agentetanerceptFDAFood and Drug AdministrationNovartis

IL-26 Plays Antimicrobial Role in Immune Response

Lara C. Pullen, PhD  |  September 28, 2015

Researchers determined IL-26 serves as a potent antimicrobial that promotes the immune sensing of both bacterial and host cell death…

Filed under:ConditionsResearch Rheum Tagged with:Autoimmune diseaseRheumatoid Arthritis (RA)Th17

FDA’s ‘Breakthrough Drug’ Terminology Confuses the Public

Kathryn Doyle  |  September 22, 2015

NEW YORK (Reuters Health)—What the Food and Drug Administration calls a ‘breakthrough’ drug is often not the same as what a layperson would call a breakthrough, a new study shows. The FDA uses the term more often, and for smaller advances, than people use it colloquially, and this may lead patients to have unwarranted confidence…

Filed under:Drug Updates Tagged with:communicationdrug developmentFDAFood and Drug AdministrationLabeling Changes

Figure 1: Hematoxylin & Eosin Staining

Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report

Paul Hoover, MD, PhD, & Lindsey MacFarlane, MD  |  September 15, 2015

A 35-year-old female with a history of systemic lupus erythematosus (SLE) without kidney involvement was admitted to our hospital with low-grade fevers, headache, increasing lower extremity edema and elevated blood pressure. History She was first diagnosed with SLE as a teenager when she developed oral ulcers and pleuritic chest pain and tested positive for anti-Smith…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:ClinicalDiagnosiskidneyoutcomepatient careSLEstemic lupus erythematosus

Connective Tissue Disorders Lack Societal Concern, Financial Support

Simon M. Helfgott, MD  |  September 15, 2015

“Love is the bone and sinew of my curse.” —Sylvia Plath Cutting the Cord Here’s the problem: No one grows up wanting to seek the cure for bursitis—or tendonitis or just about any of the other seemingly mundane maladies afflicting our body’s scaffolding. Meniscal tears, fasciitis, tendinopathies—the list is endless. Chances are, your college essay…

Filed under:ConditionsOpinionResearch RheumRheuminationsSoft Tissue PainSpeak Out Rheum Tagged with:bursitisconnective tissue disorderpatient careResearchrheumatologisttendonitis

  • « Previous Page
  • 1
  • …
  • 61
  • 62
  • 63
  • 64
  • 65
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences